&nbsp;

Mar 2024

Drug

nab-PACLitaxel

Other Name(s): Abraxane®

Quick Link(s):

Dec 2024

Regimen

MFOLFOX6+PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

FOLFIRI+PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

FEDR

Cancer Type:

Hematologic,

Myeloproliferative Neoplasms (MPNs)

Intent: Palliative

Funding:

Exceptional Access Program

fedratinib - For the treatment of splenomegaly and/or disease related symptoms of myelofibrosis according to clinical criteria

Drugs Used:

fedratinib

Quick Link(s):

Regimen Monograph

Jan 2025

Drug

avelumab

Other Name(s): Bavencio™

Quick Link(s):

Jan 2025

Drug

apalutamide

Other Name(s): Erleada®

Quick Link(s):

Jan 2025

Regimen

AVEL

Cancer Type:

Skin,

Merkel Cell

Intent: Palliative

Funding:

New Drug Funding Program

Avelumab - Metastatic Merkel Cell Carcinoma

Drugs Used:

avelumab

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

APAL

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria

Exceptional Access Program

apalutamide - For the treatment of metastatic castration sensitive prostate cancer (mCSPC), based on criteria

Drugs Used:

apalutamide

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

AVEL(MNT)

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Avelumab - Maintenance Treatment for Unresectable Locally Advanced or Metastatic Urothelial Carcinoma

Drugs Used:

avelumab

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

CISPFU+PEMB; FU+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

CRBPFU+PEMB; FU+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used: